HWHeather Walker

Heather Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heather Walker has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploration of patients’ and health care professionals’ perspectives of kidney failure risk and shared decision-making in the context of MULTIPle lOng-term condItions aNd frailTy (MULTIPOINT): a qualitative interview and focus group study

    by Heather Walker, Michael K. Sullivan, Bhautesh Dinesh Jani, Patrick B. Mark, Katie I. Gallacher

    Background: People living with chronic kidney disease (CKD) frequently experience multiple long-term conditions (multimorbidity) and/or frailty. This population is under-researched and shared decision-making in this context is challenging. Clinical guidelines recommend the kidney failure risk equation (KFRE) is used to guide CKD care and referral. This study aims to explore patients’ and healthcare professionals’ (HCPs) perspectives on CKD, including kidney failure risk, and shared decision-making in multimorbidity and/or frailty. A secondary aim is to examine perceptions of KFRE, as a guideline-recommended prognostic tool, in these populations. Methods: Semi-structured interviews with patients and focus groups for HCPs from primary and secondary care settings in Glasgow, United Kingdom were conducted March 2024-July 2025. Using a theory-informed abductive approach, data were analysed according to Normalisation Process Theory. Results: Thirty-one patients (aged 46–94 years old; 3–10 long-term health conditions; clinical frailty scale of 1–7) and nineteen HCPs participated. Five interconnected factors shaped understanding of CKD, kidney failure risk and shared decision-making, each experienced differently by patients and HCPs: (1) Variable knowledge of CKD, with many patients unaware of their diagnosis and HCPs recognising challenges within time-pressured consultations or with competing priorities; (2) Workload and burden of managing CKD within multimorbidity, including cognitive, practical and emotional demands for patients and competing priorities and complexity for HCPs; (3) Relationships and interactions, where trust and continuity facilitated shared decision-making; (4) Context and priorities, including prioritisation of CKD by patients and HCPs; and (5) Pervasive uncertainty around prognosis, symptom attribution and when to discuss kidney failure risk. KFRE was unknown to patients and most primary care HCPs, secondary care HCPs had greater awareness but expressed mixed views on its application. Conclusions: CKD was often not a priority for patients or HCPs, compared to other conditions. Many patients wanted to better understand CKD and kidney failure risk alongside other conditions. Trusting relationships, continuity of care and individual priorities were central to shared decision-making, but frequently undermined by system pressures. Methods of communicating kidney failure risk and uncertainty require further research. Findings provide insights for embedding CKD and kidney failure risk understanding into the care of individuals with multimorbidity or frailty. Trial registration: Ethical approval granted in August 2023 by the NHS Health Research Authority following a favourable opinion from the West of Scotland Research Ethics Committee (REC) 3 (IRAS ID: 325848, REC reference: 23WS/0119, Protocol number GN22RE559).

  • Open Access

    Predicting kidney failure risk without albuminuria: implications in chronic kidney disease

    by Heather Y Walker, Jennifer S Lees

  • Open Access

    The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks

    by Heather Walker, Juan-Jesus Carrero, Michael K Sullivan, Ryan Field, Anne-Laure Faucon, Jennifer S Lees, Edouard L Fu, Bhautesh Dinesh Jani, Katie Gallacher, Patrick B Mark

    Background and hypothesis: Guidelines recommend using risk prediction models for predicting kidney failure in chronic kidney disease (CKD). Many people with CKD have multiple long-term conditions (multimorbidity), which influences outcomes including kidney failure and mortality. This study validated the four-variable kidney failure risk equation (KFRE) in individuals with CKD, with and without multimorbidity, comparing performance of KFRE using creatinine and cystatin C to calculate estimated glomerular filtration rate (eGFR) and updated the model to account for competing mortality risks. Methods: Observational cohort study using research-based (UK Biobank) and population-based cohorts (Stockholm Creatinine Measurements project: SCREAM). Multimorbidity was defined as two or more long-term conditions in addition to CKD. Kidney failure was defined as long-term dialysis or kidney transplantation. KFRE performance assessment included discrimination, calibration, and overall fit at 2 and 5 years. An updated model (using the same variables as KFRE) accounting for competing mortality risks was developed and validated. Results: 14 998 of 24 489 individuals in UK Biobank (61.2%) and 30 147 of 42 902 individuals in SCREAM (70.3%) had multimorbidity. Discrimination of KFRE was good (area under curve $\ge $0.86 across eGFR equations in all cohorts, multimorbidity groups and time horizons). Kidney failure risk was under-estimated in people with multimorbidity in UK Biobank (observed/expected (O/E) ratio 1.75 at 5 years; eGFR creatinine). Conversely, calibration-in-the-large (O/E ratio) at 5 years in SCREAM was 1.05 in the multimorbidity group (eGFR creatinine). Using cystatin C compared to creatinine did not improve model performance. Cumulative incidence of death was higher with multimorbidity compared to no multimorbidity. An updated model considering competing mortality improved calibration performance over KFRE, O/E ratio 0.98 in multimorbidity group of the validation cohort (UK Biobank) at 5 years. Conclusion: Competing mortality risk is important when predicting kidney failure, particularly for people with multimorbidity. An updated model accounting for competing mortality risk, permits improved model performance.


  • Open Access

    Equity of digital self-management tools in adults with multiple long-term conditions: a scoping review protocol

    by Heather Walker, Timothy Robbins, Austen El-Osta, Lucy Stirland, David Taylor, Andy Jones, Emily McBride, Asra Aslam

    Introduction: Adults living with multiple long-term conditions (MLTC)—defined as the presence of two or more physical or mental health conditions—often face fragmented and complex care. Digital tools offer scalable self-management solutions but may exacerbate inequities due to the digital divide and other factors. The aim of this scoping review is to map and summarise the existing literature on digital self-management tools used in MLTC, with a particular focus on how equity of access is considered in their development, implementation and evaluation. Methods and analysis: Scoping review methodology will be based on the Joanna Briggs Institute guidance for scoping reviews and Arskey and O’Malley’s framework and will be reported in alignment with Preferred Reporting Items for Systematic Review and Meta-Analyses extension for Scoping Reviews. Comprehensive search terms based on ‘multimorbidity’, ‘digital tools’ and ‘self-management’ have been developed. Peer-reviewed publications will be identified using MEDLINE, Embase, Emcare, Scopus, CINAHL and PubMed. Two reviewers will independently screen titles and abstracts, with subsequent full text review also being performed in duplicate to ensure they meet the eligibility criteria. Discrepancies will be resolved by discussion with a third reviewer. Included studies will focus on digital tools for the self-management of MLTC in adults (≥18 years old) in any setting. Equity dimensions will include, but are not limited to, digital literacy, treatment burden, socioeconomic status, polypharmacy and access disparities. Ethics and dissemination: Ethical approval is not required for this scoping review. The results of the scoping review will be published in an open access, peer-reviewed journal for wider dissemination. Additionally, findings will contribute to topic guides and mapping of a research networking event with key stakeholders (including patient and public involvement and engagement members, clinicians, researchers and industry) in MLTC, around the same subject area.

  • Frailty in Adults with CKD and Validation of the Kidney Failure Risk Equation in Frailty Subgroups

    by Heather Walker, Juan-Jesus Carrero, Michael K. Sullivan, Ryan Field, Jennifer S. Lees, Peter Hanlon, Anne-Laure Faucon, Edouard L. Fu, Giorgi Beridze, Bhautesh Dinesh Jani, et al.

    Key Points: The four-variable kidney failure risk equation (KFRE) does not accurately estimate kidney failure risk in frail individuals. Prognostication of kidney failure is improved in frail individuals with CKD by replacing eGFR creatinine with cystatin C-based eGFR in the KFRE model. Consideration of competing mortality risk is particularly important in those with frailty and higher KFRE risk predictions. Background: Frailty is common among adults with CKD, and its presence can influence clinical outcomes, such as advancing CKD and mortality. Clinical guidelines recommend the use of the kidney failure risk equation (KFRE) to guide management of CKD. Our aim was to validate KFRE by frailty status and assess whether model performance could be improved by using cystatin C-based eGFR equations and to assess the effect of accounting for competing mortality risk. Methods: We studied adults from the prospective research cohort UK Biobank with CKD G3–5 (eGFR 2) by any of the three CKD Epidemiology Collaboration consortium eGFR equations: eGFR creatinine (eGFRcr), eGFR cystatin C (eGFRcys), and eGFR cystatin C-cystatin. Frailty was assessed by a modified frailty phenotype and two cumulative deficit frailty indices. Kidney failure was defined as long-term dialysis or kidney transplantation. Model assessment included discrimination, calibration, and overall fit at 2 and 5 years. Results: The prevalence of frailty by one or more measures was 35% (n=8533). Those classed as frail had a higher discrepancy between eGFRcys and eGFRcr compared with the nonfrail group (−15.8 versus −6.9 ml/min per 1.73 m2). Discrimination of KFRE was good (area under the receiver operating characteristic curve ≥0.88 across all frailty subgroups and eGFR equations). Kidney failure at 5 years was underestimated in individuals with frailty (observed/expected ratio, 1.70; 95% confidence interval, 1.55 to 1.85). Calibration-in-the-large improved when eGFRcr was replaced by eGFRcys (5-year observed/expected ratio, 1.20; 95% confidence interval, 1.05 to 1.35). Overestimation of kidney failure risk in analyses that do not account for competing mortality risk, compared with those that do, was most apparent in the frailty group and the higher KFRE predicted risk groups. Conclusions: KFRE underestimates kidney failure risk of individuals with CKD and frailty. Risk prediction improved for those with frailty when cystatin C-based eGFR equations are used and when analyses account for competing risk of mortality. These factors should be considered when KFRE calculation is used in clinical practice in individuals with frailty.


  • Open Access

    Multimorbidity and analgesic-related harms: a systematic review

    by Christopher H. Grant, Heather Walker, Karen N. Barnett, Patrick B. Mark, Lesley A. Colvin, Samira Bell


  • Open Access

    Analysis of the kidney failure risk equation implementation in routine clinical practice and health inequalities in chronic kidney disease care: a retrospective cohort study

    by Heather Walker, Shabana Khan, Sandosh Padmanabhan, Jill P. Pell, Jim Lewsey, Daniel Mackay, Ruth Dundas, Jocelyn M. Friday, Tran Q. B. Tran, Denise Brown, et al.

    Background: NICE guidelines recommend GPs use the kidney failure risk equation (KFRE) to identify people with chronic kidney disease (CKD) at higher risk of kidney failure. Albuminuria results are required to calculate KFRE. Aim: Analyse the implementation of KFRE into clinical practice and investigate if albuminuria testing varied amongst patients with CKD, particularly for underserved groups. Design and setting: Retrospective cohort study of 23,063 adults in Glasgow from 2013 to 2022. Method: We evaluated albuminuria testing rates and the predictive performance of KFRE in estimating 5-year kidney failure risk amongst people with CKD. Logistic regression models quantified associations between demographic/clinical variables and albuminuria testing. Amongst people who developed kidney failure, we retrospectively assessed the impact of KFRE on the timing of meeting criteria for referral to renal services. Results: Albuminuria testing was performed in 44.5% of 10,874 adults with CKD. Females (adjusted odds ratio (aOR) 0.86: 95% CI 0.79–0.93) and those with hypertension (aOR 0.69: 95% CI 0.63–0.77) were less likely to have albuminuria testing. Those aged 40–50 years (aOR 1.83: 95% CI 1.15–2.91), with diabetes (aOR 2.35: 95% CI 2.14–2.58) and living in the least socioeconomically deprived areas (aOR 1.11: 95% CI 1.00-1.23) were more likely to have albuminuria testing. Of 1,352 individuals with incident kidney failure, incorporating KFRE into referral guidelines helped identify high-risk patients early. Conclusion: KFRE could be calculated for less than half of people due to lack of albuminuria testing. Focus should be given to improving albuminuria testing and inequities identified to allow wider implementation of KFRE.


  • Open Access

    Chronic kidney disease management in primary care: challenges and possible developments

    by Heather Walker, Michael K Sullivan, Bhautesh Dinesh Jani, Katie Gallacher


  • Open Access

    Exploration of patients’ and healthcare professionals’ perspectives on kidney failure risk and the use of the kidney failure risk equation in MULTIPle lOng-term condItions aNd frailTy (MULTIPOINT) study: a qualitative interview and focus group study protocol

    by Heather Walker, Michael K Sullivan, Bhautesh Dinesh Jani, Patrick B Mark, Katie I Gallacher

    Introduction Clinical guidelines recommend the use of the kidney failure risk equation (KFRE) to guide the referral of individuals with chronic kidney disease (CKD) to secondary kidney care services. People living with CKD frequently experience multiple long-term conditions (multimorbidity) and/or frailty. This may impact patients’ or carers’ perceptions of kidney failure in the context of other health problems and associated risks and emphasises the need for shared decision-making. This paper presents the research protocol for the exploration of patients’ and healthcare professionals’ perspectives on kidney failure risk and the use of the KFRE in the MULTIPle lOng-term condItions aNd frailTy study. This study aims to investigate patient and healthcare professionals’ perspectives and expectations of the use of KFRE in individuals with CKD and multimorbidity and/or frailty, with a focus on shared decision-making. Methods and analysis Analysis of semistructured interviews with adults who have CKD and multimorbidity and/or frailty and focus groups with healthcare professionals (who are involved in caring for patients with CKD). Framework analysis, underpinned by normalisation process theory, will be used to develop codes and explore themes from the interviews and focus groups. Patient and public involvement has been pivotal to the study conceptualisation and will continue to be embedded throughout the study. Ethics and dissemination The study protocol has undergone peer review by the NHS Greater Glasgow and Clyde Research and Innovation team and has been granted ethical approval in August 2023 by the NHS Health Research Authority following a favourable opinion from the West of Scotland Research Ethics Committee (REC) 3 (IRAS ID: 325848, REC reference: 23WS/0119, Protocol number GN22RE559). The results of the research will be disseminated through peer-reviewed publications and conferences, as well as to patient and public involvement groups who have been involved in the study and through knowledge exchange events.

  • Open Access

    Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review

    by Heather Walker, Scott Day, Christopher H. Grant, Catrin Jones, Robert Ker, Michael K. Sullivan, Bhautesh Dinesh Jani, Katie Gallacher, Patrick B. Mark

    Background: Prognostic models that identify individuals with chronic kidney disease (CKD) at greatest risk of developing kidney failure help clinicians to make decisions and deliver precision medicine. It is recognised that people with CKD usually have multiple long-term health conditions (multimorbidity) and often experience frailty. We undertook a systematic review to evaluate the representation and consideration of multimorbidity and frailty within CKD cohorts used to develop and/or validate prognostic models assessing the risk of kidney failure. Methods: We identified studies that described derivation, validation or update of kidney failure prognostic models in MEDLINE, CINAHL Plus and the Cochrane Library—CENTRAL. The primary outcome was representation of multimorbidity or frailty. The secondary outcome was predictive accuracy of identified models in relation to presence of multimorbidity or frailty. Results: Ninety-seven studies reporting 121 different kidney failure prognostic models were identified. Two studies reported prevalence of multimorbidity and a single study reported prevalence of frailty. The rates of specific comorbidities were reported in a greater proportion of studies: 67.0% reported baseline data on diabetes, 54.6% reported hypertension and 39.2% reported cardiovascular disease. No studies included frailty in model development, and only one study considered multimorbidity as a predictor variable. No studies assessed model performance in populations in relation to multimorbidity. A single study assessed associations between frailty and the risks of kidney failure and death. Conclusions: There is a paucity of kidney failure risk prediction models that consider the impact of multimorbidity and/or frailty, resulting in a lack of clear evidence-based practice for multimorbid or frail individuals. These knowledge gaps should be explored to help clinicians know whether these models can be used for CKD patients who experience multimorbidity and/or frailty. Systematic review registration: This review has been registered on PROSPERO (CRD42022347295).